Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06143319
Other study ID # B670201422908 - EC/2014/1245
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 1, 2015
Est. completion date October 30, 2021

Study information

Verified date November 2023
Source University Ghent
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Although the cause of persistent non-specific low back pain (LBP) remains unknown, structural and functional alterations of the brain, alterations in the lumbar muscles and dysfunction of the central nervous system have been proposed as underlying mechanisms. In this case-control study, 1) brain structure/function, 2) lumbar muscle function and 3) central pain processing are compared across four groups: 1) healthy participants, 2) recurrent LBP (both during pain flare and during pain remission), 3) chronic LBP and 4) fibromyalgia. According to previous research, healthy participants and fibromyalgia patients are two extremes of a "musculoskeletal pain continuum". Healthy participants representing one extreme of the continuum with no pain and fibromyalgia representing the other extreme of the continuum with chronic widespread pain. It is thought that different LBP populations (i.e. (sub)acute, recurrent, chronic LBP) float between the aforementioned extremes. Past studies already highlighted the need for studies comparing the pathophysiological mechanisms for different pain syndromes to identify common underlying mechanisms across pain syndromes. For this reason, the goal of the current study is to compare alterations in brain structure/function, alterations in lumbar muscle function and alterations in central pain processing across the aforementioned "musculoskeletal pain continuum". It is hypothesized that longer duration of pain (recurrent vs chronic) and the extensiveness of the pain (one location vs widespread pain) are associated with more pronounced alterations in 1) brain structure/function, 2) lumbar muscle function and 3) central pain processing.


Description:

Introduction: Chronic pain is one of the most disabling symptoms in several medical conditions, including LBP and fibromyalgia. A crucial factor for the persistence of recurrent/chronic pain are alterations in lumbar muscle structure and function in patients experiencing recurrent/chronic LBP. Previous studies revealed that these alterations in lumbar muscle structure and function do not resolve when patients with recurrent LBP experience a pain-free episode. According to other recent studies, dysfunction of the central nervous system is another crucial factor to the maintenance of chronic pain. The aforementioned alterations in lumbar muscle structure and function could constitute constant nociceptive input leading to the development of central sensitization (i.e. heightened sensitivity or hyperexcitability of central nervous system). Although it is plausible that central sensitization and disturbed pain processing do exist in patients experiencing chronic LBP, previous studies investigating these mechanisms are scant and results are inconsistent. These inconsistent results might be explained by the fact that previous studies used mixed back pain populations (i.e. different types of back pain are included in one study). In contrast to the inconsistent evidence for the presence of central sensitization in chronic LBP, previous studies in fibromyalgia populations have shown convincing evidence for central sensitization and disturbed pain processing in fibromyalgia. It could be possible that the long-term presence of pain and nociceptive input not only influence pain processing, but also motor control. To support this hypothesis, past studies have revealed altered organization of brain areas involved in trunk and lumbar motor control in patients experiencing recurrent LBP. In addition to alterations in brain function, changes in brain structure are also probable in patients experiencing persistent pain and nociceptive input. Previous studies in fibromyalgia already confirmed the presence of structural brain alterations. To date, only two studies investigated the presence of structural brain alterations in gray matter in patients experiencing LBP and the results are contradicting. Whether structural brain alterations in white matter exist in patients experiencing LBP has not yet explored in previous studies. Past studies in fibromyalgia do confirm that white matter structural changes exist. It is still unclear which specific properties of white matter change in patients with fibromyalgia, because more advanced imaging techniques are necessary to answer this question. In our current study we want to elaborate on the aforementioned results obtained in fibromyalgia patients to investigate whether the same alterations in central mechanisms (i.e. altered pain processing and alterations in brain structure/function) occur in patients experiencing recurrent/chronic LBP. Past studies already highlighted the need for studies comparing similarities and differences in the pathophysiological mechanisms for different pain syndromes to identify similarities in underlying mechanisms across different pain syndromes (e.g. fibromyalgia and LBP). For this reason, the current study will include both patients with fibromyalgia and patients experiencing recurrent/chronic LBP to allow for comparison of the pathophysiological mechanisms. This case-control study has multiple goals: 1) investigate whether central sensitization and disturbed central pain processing are present in patients experiencing recurrent and chronic LBP. 2) investigate whether structural alterations in gray and white matter exist in patients experiencing recurrent and chronic LBP. 3) investigate whether alterations in white matter microstructure exist in patients experiencing recurrent and chronic LBP and if these alterations are comparable to alterations in white matter structure in fibromyalgia reported in previous studies. 4) investigate whether there is an association between alterations in brain structure/functional connectivity and the degree of disturbances in pain processing. 5) investigate whether there is an association between alterations in brain structure/functional connectivity and lumbar muscle dysfunction. 6) investigate to what extent the duration of pain (i.e. (sub)acute, recurrent, chronic) and the extensiveness of pain (i.e. one location vs widespread pain) influences lumbar motor control, pain processing and brain structure/function. Method: In this case-control study, 80 female participants will be divided over 4 groups: 1) healthy participants (N=20), 2) recurrent non-specific LBP patients, both during pain remission and during pain flare pain (N = 20), 3) chronic non-specific LBP (N = 20) and 4) fibromyalgia patients (N = 20). The test protocol consists of three parts: 1) participants complete a series of questionnaires measuring several clinical characteristics, including: sociodemographic variables, pain intensity, functional disability, central sensitization and psychosocial factors (i.e. coping, catastrophizing, kinesiophobia, hypervigilance and anxiety/depression). 2) magnetic resonance imaging (MRI) will be used to measure brain structure. Functional MRI (fMRI) and diffusion tensor imaging (DTI) will be used to measure brain function (i.e. resting state and functional connectivity respectively). 3) a series of clinical tests will be performed to measure lumbar muscle function and central pain processing. Lumbar muscle function will be evaluated by using surface electromyography (EMG) for testing anticipatory postural adjustments (APA) in a rapid arm movement (RAM) task and compensatory postural adjustments (CPA) in a quick force release test (QFRT). Central pain processing will be assessed by using 1) pressure algometry for determining pain pressure thresholds (PPT), 2) measuring PPT after a conditioned pain modulation paradigm (CPM) and 3) by determining the nociceptive flexion reflex (NFR) threshold by using repetitive transcutaneous electrical nerve stimulation (TENS) of the n. suralis.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date October 30, 2021
Est. primary completion date October 30, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: 1. Dutch speaking female participants (age between 18 and 45 years). 2. Non-specific recurrent LBP patients experiencing a period of remission at the moment of testing. Patients have to meet the criteria for recurrent LBP (in remission) as described by De Vet et al. (2002) and D'Hooge et al. (2013). 3. Non-specific recurrent LBP patients experiencing a pain flare at the moment of testing. Patients have to meet the criteria for recurrent LBP (during pain flare) as described by De Vet et al. (2002) and D'Hooge et al. (2013). 4. Participants experiencing non-specific chronic LBP (meeting the International Association for the Study of Pain [IASP] criteria) 5. Participants diagnosed with fibromyalgia according to the American College of Rheumatology (ACR) criteria (2010) 6. Healthy volunteers with no history of serious respiratory, orthopedic, neurologic or circulatory conditions. No history of low back pain (i.e. low back pain in this case is defined as a period of symptoms lasting a minimum of 2 consecutive days and for which a paramedic is consulted). Participants with a history of spinal surgery, spinal trauma or spinal deformities are also excluded. Healthy participants will be matched for age and BMI with included participants experiencing chronic/recurrent LBP or fibromyalgia. Exclusion Criteria: 1. Pregnancy or breastfeeding in the past year 2. Contraindications for MRI (e.g. electrical/mechanical implants or electrodes in de body, eye/skin injury by metal fragments in the past, etc) 3. BMI lower than 18 or higher than 30 4. Participant performed specific trunk muscle training in the past year. 5. Participating in sports at a professional level

Study Design


Locations

Country Name City State
Belgium Ghent University, vakgroep revalidatiewetenschappen Ghent Oost-Vlaanderen

Sponsors (2)

Lead Sponsor Collaborator
University Ghent Fund for Scientific Research, Flanders, Belgium

Country where clinical trial is conducted

Belgium, 

References & Publications (32)

Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R, Sprangers MA, te Velde A, Verrips E. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol. 1998 Nov;51(11):1055-68. doi: 10.1016/s0895-4356(98)00097-3. — View Citation

Apkarian AV, Sosa Y, Sonty S, Levy RM, Harden RN, Parrish TB, Gitelman DR. Chronic back pain is associated with decreased prefrontal and thalamic gray matter density. J Neurosci. 2004 Nov 17;24(46):10410-5. doi: 10.1523/JNEUROSCI.2541-04.2004. — View Citation

Beurskens AJ, de Vet HC, Koke AJ, van der Heijden GJ, Knipschild PG. Measuring the functional status of patients with low back pain. Assessment of the quality of four disease-specific questionnaires. Spine (Phila Pa 1976). 1995 May 1;20(9):1017-28. doi: 10.1097/00007632-199505000-00008. — View Citation

Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003 Aug;35(8):1381-95. doi: 10.1249/01.MSS.0000078924.61453.FB. — View Citation

D'hooge R, Cagnie B, Crombez G, Vanderstraeten G, Achten E, Danneels L. Lumbar muscle dysfunction during remission of unilateral recurrent nonspecific low-back pain: evaluation with muscle functional MRI. Clin J Pain. 2013 Mar;29(3):187-94. doi: 10.1097/AJP.0b013e31824ed170. — View Citation

D'hooge R, Cagnie B, Crombez G, Vanderstraeten G, Dolphens M, Danneels L. Increased intramuscular fatty infiltration without differences in lumbar muscle cross-sectional area during remission of unilateral recurrent low back pain. Man Ther. 2012 Dec;17(6):584-8. doi: 10.1016/j.math.2012.06.007. Epub 2012 Jul 10. — View Citation

D'hooge R, Hodges P, Tsao H, Hall L, Macdonald D, Danneels L. Altered trunk muscle coordination during rapid trunk flexion in people in remission of recurrent low back pain. J Electromyogr Kinesiol. 2013 Feb;23(1):173-81. doi: 10.1016/j.jelekin.2012.09.003. Epub 2012 Oct 15. — View Citation

Danneels LA, Coorevits PL, Cools AM, Vanderstraeten GG, Cambier DC, Witvrouw EE, De CH. Differences in electromyographic activity in the multifidus muscle and the iliocostalis lumborum between healthy subjects and patients with sub-acute and chronic low back pain. Eur Spine J. 2002 Feb;11(1):13-9. doi: 10.1007/s005860100314. — View Citation

Danneels LA, Vanderstraeten GG, Cambier DC, Witvrouw EE, De Cuyper HJ. CT imaging of trunk muscles in chronic low back pain patients and healthy control subjects. Eur Spine J. 2000 Aug;9(4):266-72. doi: 10.1007/s005860000190. — View Citation

de Vet HC, Heymans MW, Dunn KM, Pope DP, van der Beek AJ, Macfarlane GJ, Bouter LM, Croft PR. Episodes of low back pain: a proposal for uniform definitions to be used in research. Spine (Phila Pa 1976). 2002 Nov 1;27(21):2409-16. doi: 10.1097/01.BRS.0000030307.34002.BE. — View Citation

Fayed N, Garcia-Campayo J, Magallon R, Andres-Bergareche H, Luciano JV, Andres E, Beltran J. Localized 1H-NMR spectroscopy in patients with fibromyalgia: a controlled study of changes in cerebral glutamate/glutamine, inositol, choline, and N-acetylaspartate. Arthritis Res Ther. 2010;12(4):R134. doi: 10.1186/ar3072. Epub 2010 Jul 7. — View Citation

Hodges PW, Moseley GL. Pain and motor control of the lumbopelvic region: effect and possible mechanisms. J Electromyogr Kinesiol. 2003 Aug;13(4):361-70. doi: 10.1016/s1050-6411(03)00042-7. — View Citation

Kang DH, Son JH, Kim YC. Neuroimaging studies of chronic pain. Korean J Pain. 2010 Sep;23(3):159-65. doi: 10.3344/kjp.2010.23.3.159. Epub 2010 Aug 26. — View Citation

Kraaimaat FW, Evers AW. Pain-coping strategies in chronic pain patients: psychometric characteristics of the pain-coping inventory (PCI). Int J Behav Med. 2003;10(4):343-63. doi: 10.1207/s15327558ijbm1004_5. — View Citation

Kregel J, Vuijk PJ, Descheemaeker F, Keizer D, van der Noord R, Nijs J, Cagnie B, Meeus M, van Wilgen P. The Dutch Central Sensitization Inventory (CSI): Factor Analysis, Discriminative Power, and Test-Retest Reliability. Clin J Pain. 2016 Jul;32(7):624-30. doi: 10.1097/AJP.0000000000000306. — View Citation

Lutz J, Jager L, de Quervain D, Krauseneck T, Padberg F, Wichnalek M, Beyer A, Stahl R, Zirngibl B, Morhard D, Reiser M, Schelling G. White and gray matter abnormalities in the brain of patients with fibromyalgia: a diffusion-tensor and volumetric imaging study. Arthritis Rheum. 2008 Dec;58(12):3960-9. doi: 10.1002/art.24070. — View Citation

Meeus M, Nijs J. Central sensitization: a biopsychosocial explanation for chronic widespread pain in patients with fibromyalgia and chronic fatigue syndrome. Clin Rheumatol. 2007 Apr;26(4):465-73. doi: 10.1007/s10067-006-0433-9. Epub 2006 Nov 18. — View Citation

Neziri AY, Curatolo M, Limacher A, Nuesch E, Radanov B, Andersen OK, Arendt-Nielsen L, Juni P. Ranking of parameters of pain hypersensitivity according to their discriminative ability in chronic low back pain. Pain. 2012 Oct;153(10):2083-2091. doi: 10.1016/j.pain.2012.06.025. Epub 2012 Jul 28. — View Citation

Nijs J, Daenen L, Cras P, Struyf F, Roussel N, Oostendorp RA. Nociception affects motor output: a review on sensory-motor interaction with focus on clinical implications. Clin J Pain. 2012 Feb;28(2):175-81. doi: 10.1097/AJP.0b013e318225daf3. — View Citation

Nijs J, Inghelbrecht E, Daenen L, Hachimi-Idrissi S, Hens L, Willems B, Roussel N, Cras P, Wouters K, Bernheim J. Recruitment bias in chronic pain research: whiplash as a model. Clin Rheumatol. 2011 Nov;30(11):1481-9. doi: 10.1007/s10067-011-1829-8. Epub 2011 Aug 19. — View Citation

Roelofs J, Peters ML, McCracken L, Vlaeyen JWS. The pain vigilance and awareness questionnaire (PVAQ): further psychometric evaluation in fibromyalgia and other chronic pain syndromes. Pain. 2003 Feb;101(3):299-306. doi: 10.1016/S0304-3959(02)00338-X. — View Citation

Roland M, Morris R. A study of the natural history of back pain. Part I: development of a reliable and sensitive measure of disability in low-back pain. Spine (Phila Pa 1976). 1983 Mar;8(2):141-4. doi: 10.1097/00007632-198303000-00004. No abstract available. — View Citation

Roussel NA, Nijs J, Meeus M, Mylius V, Fayt C, Oostendorp R. Central sensitization and altered central pain processing in chronic low back pain: fact or myth? Clin J Pain. 2013 Jul;29(7):625-38. doi: 10.1097/AJP.0b013e31826f9a71. — View Citation

Schmidt-Wilcke T, Leinisch E, Ganssbauer S, Draganski B, Bogdahn U, Altmeppen J, May A. Affective components and intensity of pain correlate with structural differences in gray matter in chronic back pain patients. Pain. 2006 Nov;125(1-2):89-97. doi: 10.1016/j.pain.2006.05.004. Epub 2006 Jun 5. — View Citation

Silfies SP, Mehta R, Smith SS, Karduna AR. Differences in feedforward trunk muscle activity in subgroups of patients with mechanical low back pain. Arch Phys Med Rehabil. 2009 Jul;90(7):1159-69. doi: 10.1016/j.apmr.2008.10.033. Epub 2009 Jun 5. — View Citation

Tsao H, Danneels LA, Hodges PW. ISSLS prize winner: Smudging the motor brain in young adults with recurrent low back pain. Spine (Phila Pa 1976). 2011 Oct 1;36(21):1721-7. doi: 10.1097/BRS.0b013e31821c4267. — View Citation

Van Oosterwijck J, Nijs J, Meeus M, Lefever I, Huybrechts L, Lambrecht L, Paul L. Pain inhibition and postexertional malaise in myalgic encephalomyelitis/chronic fatigue syndrome: an experimental study. J Intern Med. 2010 Sep;268(3):265-78. doi: 10.1111/j.1365-2796.2010.02228.x. Epub 2010 Mar 3. — View Citation

Van Oosterwijck J, Nijs J, Meeus M, Van Loo M, Paul L. Lack of endogenous pain inhibition during exercise in people with chronic whiplash associated disorders: an experimental study. J Pain. 2012 Mar;13(3):242-54. doi: 10.1016/j.jpain.2011.11.006. Epub 2012 Jan 24. — View Citation

Vlaeyen JWS, Kole-Snijders AMJ, Boeren RGB, van Eek H. Fear of movement/(re)injury in chronic low back pain and its relation to behavioral performance. Pain. 1995 Sep;62(3):363-372. doi: 10.1016/0304-3959(94)00279-N. — View Citation

Wacholder S, Silverman DT, McLaughlin JK, Mandel JS. Selection of controls in case-control studies. III. Design options. Am J Epidemiol. 1992 May 1;135(9):1042-50. doi: 10.1093/oxfordjournals.aje.a116398. — View Citation

Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010 May;62(5):600-10. doi: 10.1002/acr.20140. — View Citation

Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70. doi: 10.1111/j.1600-0447.1983.tb09716.x. — View Citation

* Note: There are 32 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Brain structure and function The scanning session will comprise of (1) whole-brain T1-weighted structural MRI, (2) whole-brain DTI and (3) whole-brain resting-state functional MRI (rs-fMRI). The entirety of the protocol for each patient is administered in a single day, spanning approximately 4 to 5 hours.
Primary Pressure pain thresholds Pressure algometry for determining the PPT with a digital algometer bilaterally at three body locations, namely on the forearm (on the muscle belly of the extensor carpi radialis muscle), the erector spinae (5cm lateral to the processus spinosus of vertebra L3), and the calf (at the upper third of the distance between the knee crease and the distal border of the calcaneus) The entirety of the protocol for each patient is administered in a single day, spanning approximately 4 to 5 hours.
Primary Conditioned pain modulation A CPM paradigm during which the PPT (= test stimulus) is repeated during and after immersion of the non-dominant hand in a warm water bath (= conditioned stimulus) of 45.5°C for six minutes. The entirety of the protocol for each patient is administered in a single day, spanning approximately 4 to 5 hours.
Primary Nociceptive flexion reflex thresholds Repetitive TENS of the sural nerve of the dominant leg to determine the NFR threshold and temporal summation of the NFR threshold. A bar stimulating electrode will be connected to a constant current stimulator. Elicitation of the NFR will be evaluated by measuring the involuntary contraction of the ipsilateral biceps femoris. The entirety of the protocol for each patient is administered in a single day, spanning approximately 4 to 5 hours.
Primary Lumbar muscle function Lumbar muscle function will be measured by using surface EMG for testing APAs in a RAM test and CPAs in a QFRT. The entirety of the protocol for each patient is administered in a single day, spanning approximately 4 to 5 hours.
Secondary Pain intensity Pain intensity was measured with two visual analogue scales (0 - 100) for average pain and worst pain. The anchors are 'no pain' and 'unbearable pain' respectively. No grid lines are shown on the scale. The entirety of the protocol for each patient is administered in a single day, spanning approximately 4 to 5 hours.
Secondary Functional disability To measure functional disability the Dutch version (Beurskens, De Vet et al. 1995) of the Roland and Morris Disability Questionnaire (RMDQ) (Roland and Morris 1983) was used. The RMDQ consists of 24 items, with dichotomous answers: 'Yes' (coded = 1) or 'No' (coded = 0). Scores range from 0-24. Higher scores indicate higher disability. The entirety of the protocol for each patient is administered in a single day, spanning approximately 4 to 5 hours.
Secondary Coping Coping was measured by using the Dutch version of the Pain Coping Inventory (PCI) (Kraaimaat, Bakker et al. 1997). The PCI consists of 33 questions divided over six subscales: pain transformation, distraction, reducing demands, retreating, worrying and resting (Kraaimaat and Evers 2003). Participants have to rate on 4-point Likert scales to what extend they perform the described behaviors in the statements (e.g. "I take a bath or shower"). Based on the scores of the 33 items, 2 higher order scores are derived for active coping (i.e. transformation, reducing demands, distraction) and passive coping (i.e. retreating, worrying and resting). The entirety of the protocol for each patient is administered in a single day, spanning approximately 4 to 5 hours.
Secondary Kinesiophobia To measure pain related fear, the Dutch version of the Tampa Scale for Kinesiophobia (TSK) was used (Vlaeyen, Kole-Snijders et al. 1995). The TSK is used to measure the extend of pain-related fear and the influence on activity level in LBP populations. The questionnaire consists of 17 items, with higher scores indicating a higher degree of kinesiophobia. Items are scored on 4-point Likert scales and participants have to rate to what degree they agree/disagree to the statements (e.g. "I'm afraid that I might injure myself if I exercise"). The entirety of the protocol for each patient is administered in a single day, spanning approximately 4 to 5 hours.
Secondary Catastrophizing To measure pain catastrophizing the Dutch version (Crombez 1996) of the Pain Catastrophizing Scale (PCS) was used. The PCS consist of 13 items about past painful experiences. Participants were requested to indicate to what degree they experience certain thoughts or feelings when experiencing pain on a 5-point Likert scale (e.g.: "I worry all the time about whether the pain will end"). The total score ranges from 0-52, with higher scores indicating more pain catastrophizing. The entirety of the protocol for each patient is administered in a single day, spanning approximately 4 to 5 hours.
Secondary Depression and anxiety To measure symptoms of depression and anxiety, the Dutch version of the Hospital Anxiety and Depression Scale (HADS) was used (Zigmond and Snaith, 1983). The HADS consists of two subscales with 7 items. Scores on both subscales ranges from 0 - 20, with higher scores indicating more anxiety and/or depression. Participants have to indicate on a 4-point Likert scale if they have experienced the emotions described in each statement during the last week (e.g. "I feel restless as I have to be on the move"). The entirety of the protocol for each patient is administered in a single day, spanning approximately 4 to 5 hours.
Secondary Central sensitization The Dutch version of the Central Sensitization Index (CSI) was used to measure for symptoms and clinical features related to central sensitization (i.e. hyperexcitability of the central nervous system) (Kregel, Vuijk et al. 2016). The CSI consists of two parts. The first part measures to what extend somatic and emotional symptoms related to central sensitization are present (e.g. "I get tired very easily when I am physically active") and the second part measures whether participants had earlier diagnosis which are frequently observed in central sensitization of the central nervous system (e.g. fibromyalgia, chronic fatigue syndrome, etc). The entirety of the protocol for each patient is administered in a single day, spanning approximately 4 to 5 hours.
Secondary Attention to pain To measure attention to pain, the Dutch version of the Pain Vigilance and Awareness Questionnaire (PVAQ) was used (Roelofs, Peters et al. 2003). The PVAQ consists of 16 items with two subscales: 'attention to pain' and 'attention to changes in pain'. Participants have to rate on a 6-point Likert scale to what extend they react in a certain way to pain as described in the statements (e.g. "I am quick to notice changes in pain intensity"). The entirety of the protocol for each patient is administered in a single day, spanning approximately 4 to 5 hours.
Secondary Physical activity The Dutch version of the International Physical Activity Questionnaire (IPAQ) was used to obtain a self-reported estimate of physical activity in the last seven days (Craig, Marshall et al. 2003). The IPAQ consists of 31 items about physical activity divided over 5 areas: job-related, transportation, housework (i.e. house maintenance, caring for family), recreation/sport/leisure and time spent sitting. The overall score places participants in one of three categories: 1) low/inactive, 2) moderately active and 3) highly active. The entirety of the protocol for each patient is administered in a single day, spanning approximately 4 to 5 hours.
Secondary General health status To measure general health status and health-related quality of life the Short Form Health Survey-36 items (SF-36) was used (Van der Zee and Sanderman 1993, Aaronson, Muller et al. 1998). The SF-36 measures several domains of health-related areas: physical functioning, physical role limitations, bodily pain, general health perception, energy/vitality, social functioning, emotional role limitations and mental health. Scores range from 0 - 100, higher scores indicating higher subjective health status. The entirety of the protocol for each patient is administered in a single day, spanning approximately 4 to 5 hours.
See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1